ASCO 2021

2021-06-04 - 2021-06-08
Online, Virtual

St. Gallen BCC 2021

2021-03-17 - 2021-03-21
Online, Virtual

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria
Search in Scientific Content:
Date
Filters:
Expanded e
10:42

Expanded efficacy and safety data from CheckMate 649

Presenter: Markus Moehler
ASCO 2021
Current st
8:18

Current state of frontline immunotherapy options in the treatment of NSCLC

Presenter: Federico Cappuzzo
ASCO 2021
Clinical d
9:37

Clinical decision making in the treatment of melanoma

Presenter: Paolo A. Ascierto
ASCO 2021
State of t
7:15

State of the art treatment of prostate cancer

Presenter: Oliver Sartor
ASCO 2021
State of t
5:21

State of the art treatment of breast cancer

Presenter: Virginia G. Kaklamani
ASCO 2021
State of t
17:01

State of the art treatment of multiple myeloma

Presenter: Andrzej Jakubowiak
ASCO 2021
Current st
13:02

Current state of immunotherapy options in the treatment of RCC

Presenter: Camillo Porta
ASCO 2021
Effect of
12:51

Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.

Presenter: Rajwanth Veluswamy
ASCO 2021
Current st
11:17

Current state of immunotherapy options in the treatment of melanoma

Presenter: Jeffrey Weber
ASCO 2021
State of t
17:17

State of the art treatment of breast cancer

Presenter: Jane Lowe Meisel
ASCO 2021
Response a
6:58

Response and survival results up to five years from the KEYNOTE-052 phase 2 study

Presenter: Arjun Vasant Balar
ASCO 2021
Expanded e
6:07

Expanded efficacy and safety analyses from CheckMate 577

Presenter: Ronan Joseph Kelly
ASCO 2021
IMpower010
5:36

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer

Presenter: Heather A. Wakelee
ASCO 2021
Relatlimab
6:55

Relatlimab plus nivolumab versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047

Presenter: Evan J. Lipson
ASCO 2021
ODENZA: A
4:28

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Presenter: Emeline Colomba
ASCO 2021
Detailed s
16:51

Detailed summary of the Consensus Session of the SG-BCC 2021

Presenter: Walter Weber
Specialty: Breast Cancer
St. Gallen BCC 2021
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer